Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X:
“Clinical AI tool that reads a routine HandE slide from diagnosis to identify which mHSPC patients benefit from ARSI enzalutamide. APIC, presented at ASCO26 from ENZAMET.
APIC was derived in CHAARTED and locked before ENZAMET analysis. Independent validation in 492 patients from the ENZAMET biomarker cohort.
Outcomes:
- APIC-Negative (64%): +18.2% 5-yr OS from enzalutamide
- APIC-Positive (36%): -3.2% 5-yr OS from enzalutamide
Significant treatment-biomarker interaction. Holds in multivariable analysis adjusting for volume, timing, PS, and Gleason. Not explained by docetaxel use.
No special assay or new test. Just a pathology slide you probably already have.”
Other articles featuring Katy Beckermann.
